Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Stocks in this Quantisnow insightHealth Care
Historical context for CATX
Across the 8 sessions after earlier CATX headlines, the stock closed higher 5 times and lower 2 times, with a median move of 3.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CATX | SPY |
|---|---|---|---|
| Dec 18, 2025 | Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | +3.1% | +0.8% |
| Dec 4, 2025 | Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium | +8.1% | +0.1% |
| Nov 24, 2025 | Truist resumed coverage on Perspective Therapeutics with a new price target | +3.8% | +1.5% |
| Nov 20, 2025 | Perspective Therapeutics to Participate in Upcoming December Conferences | -7.8% | -1.5% |
| Nov 11, 2025 | Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results | +0.0% | +0.2% |
| Oct 31, 2025 | Perspective Therapeutics to Participate in Upcoming November Conferences | +3.4% | +0.3% |
Quantisnow market dataAMEX
CATX
Perspective Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for CATX
Full CATX profile on Quantisnow Follow CATX and get a push notification the moment its next story breaks.